News

Forest Laboratories and Almirall have announced positive top-line results from ACCORD COPD I, a three-month phase III study comparing aclidinium 200ug and 400ug BID versus placebo. Aclidinium bromide

The collaboration aims to improve diagnosis and management of disease in critical care settings within hospitals, such as emergency departments, coronary units and ICUs. The new alliance unites

Elixir Pharmaceuticals has reported that its partner, Siena Biotech has commenced phase 1 clinical testing of Elixir’s potent, first-in-class SIRT1 (sirtuin-1) inhibitor for the treatment of huntington’s disease.

Cell Medica has entered into an R&D agreement with the Center for Cell and Gene Therapy (Center), a joint program of Baylor College of Medicine. The agreement forms

Novo Nordisk and the Swedish university consortium, ‘Combine’ have formed a research collaboration in the field of autoimmune diseases. Under the agreement, Novo Nordisk will work with scientists

Robinson Pharma (RPI) has joined the Council for Responsible Nutrition (CRN) as a full voting member. Robinson is expected to contribute to the overall health and success of

Ardea Biosciences (Ardea) has reported additional positive results from a recently completed Phase 2a study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.

Teva has entered into two agreements with AstraZeneca to settle patent litigation regarding Teva’s US generic versions of AstraZeneca’s Prilosec (omeprazole) and Nexium (esomeprazole), including all claims for

When approved for use with venous whole blood, the OraQuick HCV test is expected to be the first rapid HCV test approved by the FDA for use in